The 401(ai) Waiting Room: The Bench Explained

The strangest, most likable piece of Marc Chaikin’s new 401(ai) presentation is its third report. Alongside the five-stock portfolio and the five-stock sell list sits “The 401(ai) Waiting Room”: eight companies Chaikin says he likes but will not recommend yet, each documented with the reason it is still waiting. We have read hundreds of these packages, and a promo that publishes its own bench is rare enough to deserve an explainer. Our full 401(ai) teardown covers the presentation in detail.

What the Waiting Room Is

In the pitch’s own framing, the waiting room holds companies “I believe deserve a place on the radar, but I want more evidence.” The host, Tom Mustin, describes them as “eight companies you like but aren’t recommending.” Each entry comes with the specific missing signal: the factor or evidence that has not yet turned, the thing that would move the stock from the bench into the portfolio.

That is a genuinely different offer than the standard two-list close. Most AI promos sell certainty: a winners list and a danger list, both presented as finished verdicts. The waiting room sells a process instead. It says, in effect: here is what the 20-factor Power Gauge sees, here is what it does not see yet, and here is the trigger that changes our mind. Chaikin’s own summary of the standard: “I think of them more like 20 witnesses,” and a case needs most of the witnesses, not two or three. For the waiting-room names, in the pitch’s language, “one or two of my witnesses” are “beginning to turn but that’s not enough.”

Why It Matters

The waiting room does three things for the reader.

It makes the system checkable. A rating that publishes its thresholds invites you to watch whether the promotion happens when the evidence arrives. That is falsifiable in a way most promo claims are not.

It defines the difference between liking a stock and recommending one. The 401(ai)’s portfolio rule is apparently strict: five names, all factors agreeing, exit criteria written down. The waiting room is where “interesting” goes to wait for “investable,” and the distinction is the whole discipline. As Chaikin puts it elsewhere in the pitch: “I didn’t create a list of A.I. stocks. That would have taken me an afternoon.”

It models the right behavior for the target audience. The pitch is aimed at savers who are “afraid to buy and then also afraid not to buy,” and the waiting room demonstrates the third option most paralysis sufferers forget: watchlist, criteria, patience. The pitch’s diagnosis of doing nothing is “That’s how people end up doing nothing,” and the waiting room is its answer.

Why Eight Instead of Five or Fifty

The waiting room’s size is a deliberate design choice, and the reasoning Chaikin gives on camera is worth quoting because it says a lot about how the service thinks about discipline. The main portfolio is five stocks because “I don’t want somebody who’s already nervous about retirement trying to choose among 40 different stocks across five different AI sectors. That’s how people end up doing nothing.” The waiting room is eight because the middle ground is where discipline lives: too few names and you have no pipeline, too many and the audience freezes. Each watchlist company has one or two of the “20 witnesses” turning positive, and the specific missing signal is documented per name, so a subscriber can watch the evidence accumulate rather than guessing.

That structure also encodes an honest admission most stock-picking services never make: that conviction is a spectrum, not a switch. The same system that rates the portfolio’s five names bullish rates the waiting room’s eight as “not yet,” and the difference between the two lists is the threshold at which enough factors point the same way. For a subscriber, the waiting room is the part of the package that teaches the method rather than just delivering its outputs, and it is the reason the 401(ai) reads more like a research service than a picks list. The updates when evidence changes, “when the evidence materially changes, I want you to hear from me,” close the loop between the two tiers.

The Package Around It

The full 401(ai) offer: the five-stock model portfolio (“the companies that I believe give you the clearest way to keep a portion of your money focused on the upper arm of the K”), the “Five Stocks to Sell Now” companion report for the falling arm (“the most expensive four words in investing can be, I’ll just hold on”) — we cover the sell list separately — and the waiting room, plus updates “when the evidence materially changes, I want you to hear from me.” Value anchored over $2,000, actual price behind the order-page click, and a 30-day full refund: “for any reason or for no reason at all.”

The honest caveats: the eight waiting-room names are membership content, like everything else in the package; the historical demonstrations around them (Occidental, Vertiv, Lumentum, AppLovin (APP)) are winners shown after the fact; and the pitch’s one volunteered miss, Braze, is the reminder that even a full bench does not make a system clairvoyant. “The Power Gauge is not a crystal ball. It never has been.” Our 401(ai) overview covers the full offer, and the K-shaped economy explainer covers the frame the picks implement.

The Honest Read

The waiting room is the part of the 401(ai) we would point a skeptical reader to first, because it is the part that could embarrass the publisher. A waiting list with named triggers is a public prediction about the system’s own future behavior, and most promos avoid making those. Whether the promotions happen on schedule is exactly the kind of thing a subscriber can verify over a year, which makes the 30-day trial window a reasonable time to at least see the structure. Curiosity is a fine reason to look. Verification is a better one, and the waiting room makes verification possible in a way winner lists never do.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.